BRD5631 is an autophagy enhancer that acts through an mTOR-independent pathway; it modulates several autophagy-related cellular disease phenotypes, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production; it suppresses IL-1β secretion in an autophagy-dependent manner.